A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy.
Information source: Ortho Biotech Products, L.P.
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Anemia; Neoplasms
Intervention: Epoetin Alfa (Drug)
Phase: Phase 3
Status: Terminated
Sponsored by: Ortho Biotech Products, L.P. Official(s) and/or principal investigator(s): Ortho Biotech Products, L.P. Clinical Trial, Study Director, Affiliation: Ortho Biotech Products, L.P.
Summary
The purpose of this study is to evaluate the effectiveness and safety of PROCRIT (Epoetin
alfa) administered at 40,000 Units weekly in cancer patients that are not receiving
chemotherapy or radiation therapy.
Clinical Details
Official title: A Pilot Study to Evaluate the Response Rate of PROCRIT (Epoetin Alfa) at 40,000 Units Once Weekly in Anemic Cancer Patients Not Receiving Chemotherapy
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Hematologic response in terms of hemoglobin and transfusion requirements where hemoglobin response is characterized as minor > 1g/dL Hb increase or major > 2g/dL Hb increase.
Secondary outcome: Secondary efficacy variables will include the effects of PROCRIT (Epoetin alfa) on transfusion requirements and on Quality of Life as measured by the Linear Analog Scale Assessment (LASA) tool.
Detailed description:
This is an open-label (both the researcher and the patient in the study know the treatment
that is being given), non-randomized, multi-center pilot study with the objective to
investigate the efficacy of PROCRIT (Epoetin alfa) with regard to hematopoietic response
when administered at 40,000 Units subcutaneously (under the skin) once per week in anemic
patients with cancer not receiving chemotherapy or radiation therapy. Hematological
laboratory tests (hemoglobin and hematocrit), vital signs (blood pressure) and occurrence
and severity of adverse events will be assessed throughout the study. Patients will receive
a PROCRIT (Epoetin alfa) injection (40,000 Units per injection) under the skin once every
week for a maximum of 13 weeks. Doses may be reduced depending on the patients' hemoglobin
level.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Histologically confirmed diagnosis of non-myeloid malignancy
- Baseline hemoglobin value of less than or equal to 11 g/dL unrelated to transfusion
- Patients must not be receiving or planning to receive chemotherapy or radiotherapy
within the 16-week study period. However, patients receiving hormonal therapy or
non-myelosuppressive therapies are allowable
- Female patients with reproductive potential must have a negative serum pregnancy test
at screening.
Exclusion Criteria:
- Uncontrolled hypertension
- History (within 6 months) of uncontrolled cardiac arrhythmias, or history of
pulmonary emboli, deep vein thrombosis, ischemic stroke, other arterial or venous
thrombotic events (excluding superficial thromboses), or known history of chronic
coagulation disorder
- Transfusion within 28 days prior to first dose
- Planned chemotherapy or radiation during study and no prior chemotherapy within 8
weeks or radiation within 4 weeks of study entry
- No prior treatment with Epoetin alfa or any other erythropoietic agent within the
previous two months
Locations and Contacts
Additional Information
A Pilot Study to Evaluate the Response Rate of PROCRIT (Epoetin alfa) at 40,000 Units Once Weekly in Anemic Cancer Patients Not Receiving Chemotherapy or Radiation Therapy
Starting date: September 2002
Last updated: May 17, 2011
|